Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Johnson & Johnson
(NY:
JNJ
)
145.74
+0.97 (+0.67%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Johnson & Johnson
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
91
92
Next >
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
January 12, 2024
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.
Via
Investor's Business Daily
Dividend Dynasty: 7 High-Yield Stocks for Long-Term Wealth Accumulation
January 11, 2024
Navigate 'Dividend Dynasty': Uncover seven high-yield stocks combining stable dividends with sustainable growth strategies.
Via
InvestorPlace
Walgreens Cut Its Dividend by 48%: Here Are 5 Better Dow Dividend Stocks to Buy in January
January 11, 2024
Businesses with efficient operations and growth potential open the door to dividend raises for years to come.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Why Eli Lilly Stock Skyrocketed 59% in 2023
January 11, 2024
Lilly's pipeline success in 2023 allowed it to to claim the crown as the biggest drugmaker on the planet by market cap.
Via
The Motley Fool
2 Dow Stocks to Buy Hand Over Fist in 2024 and 1 to Avoid Like the Plague
January 11, 2024
Among the Dow Jones Industrial Average's 30 time-tested components, there are two that are historically cheap and ripe for the picking, while another outperformer is riddled with issues.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
A Closer Look at Johnson & Johnson's Options Market Dynamics
January 10, 2024
Via
Benzinga
Is Johnson & Johnson Stock a Buy Now?
January 10, 2024
The pharmaceutical giant recently announced another acquisition.
Via
The Motley Fool
3 Unshakeable Dividend Stocks for Lifelong Wealth
January 10, 2024
No matter what the circumstances, passive income won’t go out of style, thus driving the case for these long-term dividend stocks.
Via
InvestorPlace
7 Stable Stocks to Buy No Matter What Happens to Interest Rates
January 10, 2024
With investors still facing uncertainty in 2024, they may find greater comfort by targeting certain stable stocks to buy.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
January 09, 2024
Via
Benzinga
Illumina Shares Trading Higher After Confirming Partnership With Johnson & Johnson Unit
January 09, 2024
Illumina, Inc. (NASDAQ: ILMN) shares are trading higher after announcing preliminary financial results for the fourth quarter (Q4) and
Via
Benzinga
Balancing Dividends and Fundamentals: The Case of NYSE:JNJ.
January 09, 2024
Why JOHNSON & JOHNSON (NYSE:JNJ) provides a good dividend, while having solid fundamentals.
Via
Chartmill
This Dividend Stock Has a $13 Billion Secret Weapon
January 09, 2024
Johnson & Johnson made a key decision last year.
Via
The Motley Fool
Health Care Company Johnson & Johnson Announces Merger With Ambrx Biopharma
January 08, 2024
Via
Benzinga
Check Out What Whales Are Doing With JNJ
January 04, 2024
Via
Benzinga
Want to Win in the Stock Market? Be Average.
January 09, 2024
Start with companies that have proven themselves.
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
January 08, 2024
Via
Benzinga
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
January 08, 2024
With Johnson & Johnson buying out Ambrx Biopharma, the win-win deal boosted AMAM stock while better positioning J&J’s oncology unit.
Via
InvestorPlace
J&J's Tentative $700M Agreement To Resolve Talc Powder-Related Lawsuits Across US States
January 08, 2024
Healthcare giant Johnson & Johnson (NYSE: JNJ) has reached a tentative agreement to pay approximately $700 million to settle an investigation
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal
January 08, 2024
Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billi
Via
Benzinga
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
January 08, 2024
The year's biggest medical conference kicked off with a melee of buyout news.
Via
Investor's Business Daily
24 Top Dividend Stocks to Buy and Hold in 2024
January 07, 2024
These stocks could deliver positive gains in the new year -- but the real money-making opportunities are over the next decade and beyond.
Via
The Motley Fool
5 Top Investing Resolutions for 2024
January 07, 2024
You don't need a fortune to start investing today.
Via
The Motley Fool
Dow Darlings: Top 3 Stocks That Will Lead the Charge in 2024
January 06, 2024
These Dow stocks will perform better than others this year and take the leaderboard for strong gains and security.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.
Via
Benzinga
Exposures
Product Safety
Illumina's MRD Technology For Cancer Testing Collaborates With Johnson & Johnson Unit
January 05, 2024
Illumina, Inc. (NASDAQ: ILMN) announced it has signed an agreement with Janssen Research & Development, a unit of Johnson & Johnson (NYSE: JNJ).
Via
Benzinga
Still Worried About a 2024 Recession? 7 Stocks to Watch.
January 04, 2024
Although many investors feel relief from avoiding a downcycle last year, those worried about a 2024 recession should see this list.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
January 04, 2024
Needham analyst forecasts positive outlook for Arcellx Inc (ACLX) in 2024, citing potential from pivotal interim readout & strong data from Phase I study, raising price target & adding to Conviction...
Via
Benzinga
Revenge of the Boring Stocks! Dividends Are Sexy Again.
January 03, 2024
Dividend stocks are leading the way in the first few days of 2024, indicating that boring is back! What that means for investors now.
Via
InvestorPlace
This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns
January 03, 2024
BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely...
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
91
92
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.